肥胖、炎症与COVID-19临床结局:一项多中心前瞻性队列研究
国际COVID-19炎症研究(ISIC)在美国和欧洲10家医院纳入4644例因COVID-19住院的成人,于入院时检测包括可溶性尿激酶纤溶酶原激活物受体(suPAR)在内的炎症标志物。多变量分析中,BMI>40者(n=485)相比非肥胖者(BMI<30,n=2358)复合结局的比值高55%(95%CI,1.21-1.98);多重中介分析中仅suPAR为BMI与复合结局间的显著中介因子,关联在65岁以下及Omicron变异前时期更强。
要点
- BMI>40的COVID-19住院患者复合结局(死亡、机械通气、肾脏替代治疗)的比值较BMI<30者高55%(95%CI,1.21-1.98)。
- 多重中介分析中,仅suPAR为BMI与复合结局间关联的显著中介因子。
- 肥胖与COVID-19不良结局的关联在65岁以下参与者及Omicron变异前时期更强。
核心结论
- 肥胖与COVID-19更差结局相关,在较年轻参与者及Omicron变异前时期尤为明显。
- 以suPAR衡量的炎症是肥胖与COVID-19结局之间关联的显著中介因子。
研究设计与样本
- 国际COVID-19炎症研究(ISIC)为前瞻性多中心观察性研究,在美国和欧洲10家医院开展。
- 参与者为2020年2月1日至2022年10月19日期间因COVID-19住院的成人。
- 于入院时检测包括可溶性尿激酶纤溶酶原激活物受体(suPAR)在内的炎症标志物。
- 分析体重指数(BMI,kg/m2)与死亡、需机械通气及肾脏替代治疗复合结局的关联,并按Omicron变异前后分层。
- 评估炎症对肥胖与结局之间关系的贡献。
主要发现
- 共纳入4644例参与者,平均年龄59.3岁,45.6%为男性,21.8%的BMI≥35。
- 多变量分析中,BMI>40者(n=485)相比非肥胖者(BMI<30,n=2358)复合结局的比值高55%(95%CI,1.21-1.98)。
- 多重中介分析中,仅suPAR为BMI与复合结局之间关联的显著中介因子。
- 肥胖与复合结局的关联在65岁以下参与者及Omicron变异前时期更强。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Obesity is a risk factor for coronavirus disease 2019 (COVID-19)-related outcomes; however, the mechanism remains unclear. OBJECTIVE: The objective of this analysis was to determine whether inflammation mediates the association between obesity and COVID-19 outcomes. METHODS: The International Study of Inflammation in COVID-19 (ISIC): A Prospective Multi-Center Observational Study Examining the Role of Biomarkers of Inflammation in Predicting Covid-19 Related Outcomes in Hospitalized Patients, was conducted at 10 hospitals in the United States and Europe. Participants were adults hospitalized specifically for COVID-19 between February 1, 2020, through October 19, 2022. Inflammatory biomarkers, including soluble urokinase plasminogen activator receptor (suPAR), were measured at admission. Associations were examined between body mass index (BMI, kg/m2) and a composite of death, need for mechanical ventilation, and renal replacement therapy, stratified by pre- and post-Omicron variants. The contribution of inflammation to the relationship between obesity and outcomes was assessed. RESULTS: Among 4644 participants (mean age 59.3, 45.6% male, 21.8% BMI ≥ 35), those with BMI > 40 (n = 485) had 55% higher odds of the composite outcome (95% CI, 1.21-1.98) compared with nonobese individuals (BMI < 30, n = 2358) in multivariable analysis. In multiple mediation analysis, only suPAR remained a significant mediator between BMI and composite outcome. Associations were amplified for participants younger than 65 years and with pre-Omicron variants. CONCLUSION: Obesity is associated with worse outcomes in COVID-19, notably in younger participants and in the pre-Omicron era. Inflammation, as measured by suPAR, is a significant mediator of the association between obesity and COVID-19 outcomes.
引用
- Hutten CG, Padalia K, Vasbinder A, et al. Obesity, Inflammation, and Clinical Outcomes in COVID-19: A Multicenter Prospective Cohort Study. J Clin Endocrinol Metab. 2024. PMID: 38635301. doi:10.1210/clinem/dgae273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。